Summary of studies giving standardised incidence ratios (SIR) of female breast cancer (C50) in NF1
| Study | Cohort size | Median follow-up (years) | Total person years of follow-up | SIR (95% CI) | ||
| Overall | <50 years | ≥50 years | ||||
| Walker et al 14 | 227 | 13.6 | 5705 | 1.87 (0.61 to 4.37) | 4.02 (1.1 to 10.3) | 0.60 (0.02 to 3.33) |
| Sharif et al 10 | 304 | 17.8 | 5411 | 3.5 (1.9 to 5.9) | 4.9 (2.4 to 8.8) | |
| Wang et al 11 | 76 | – | – | 5.2 (2.4 to 9.8) | 8.8 (3.2 to 19.2) | 2.8 (0.6 to 8.2) |
| Madanikia et al 12 | 126 | – | – | 2.68 (0.68 to 7.29)* | 4.41 (1.12 to 12.0)* | 0.94 (0.047 to 4.65)* |
| Seminog and Goldacre13 | 6739 | ‘~6’ | 2.3 (1.7 to 2.9) | |||
| Uusitalo et al 8 | 1404 | 13.4 | 20 248 | 2.82 (1.92 to 4.00) | 5.1 (2.9 to 8.1)† | 2.0 (1.2 to 3.1)† |
*Adjusted for race, NF1 prevalence and date of diagnosis.
†Calculated using Poisson regression from the published observed and expected numbers.
NF1, neurofibromatosis type 1.